{"id":"W2131592861","doi":"10.1007/s40259-015-0130-9","title":"Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib","year":2015,"lang":"en","type":"review","venue":"BioDrugs","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":68,"is_retracted":false,"has_abstract":true,"ca_institutions":"Royal Victoria Hospital","funders":"Boehringer Ingelheim","keywords":"Afatinib; Erlotinib; Gefitinib; Epidermal growth factor receptor; Lung cancer; Medicine; Oncology; Cetuximab; Internal medicine; EGFR inhibitors; Cancer research; Tyrosine kinase; Pharmacology; Cancer; Receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001889923,0.0003551209,0.0009612228,0.0003661665,0.00005247038,0.000037933,0.00008031391,0.0002504212,0.00009735123],"category_scores_gemma":[0.00004665912,0.000263131,0.0002686385,0.0004294085,0.00003237079,0.00007846375,0.00002991679,0.0002460043,0.000465284],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001135817,"about_ca_system_score_gemma":0.001111391,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002514551,"about_ca_topic_score_gemma":0.00004908415,"domain_scores_codex":[0.9984021,0.00009172167,0.0004823362,0.0004396194,0.0003366822,0.0002475418],"domain_scores_gemma":[0.9990993,0.00004366313,0.0002047447,0.0003819755,0.00008352136,0.0001867677],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00001534408,0.0002928608,0.00001479744,0.001690204,0.0001222159,0.00007306559,0.0001826577,9.716535e-7,0.000002955832,0.0001292491,0.02939402,0.9680817],"study_design_scores_gemma":[0.001403116,0.0002746443,0.00000997191,0.007694802,0.001072514,0.00001660183,0.00005156274,0.000006790677,0.00002583979,0.00001573069,0.9891906,0.0002378365],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001037964,0.9884511,0.000002810821,0.0003304755,0.0008740815,0.001708878,0.0001135804,0.00004946275,0.008365826],"genre_scores_gemma":[0.0004653912,0.9938689,0.0002229209,0.0001219506,0.0007881919,0.00030518,0.00115331,0.00005321548,0.003020886],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9678438,"threshold_uncertainty_score":0.9999821,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1326961338418439,"score_gpt":0.3950047831603708,"score_spread":0.2623086493185269,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}